Orca Bio valuation, funding and investors
Orca Bio works in cell therapy development, based in Menlo Park, United States. Founded in 2016, it has about 377 employees.
VALUATION · TODAY
$4.06B +6% after Series F
Range $2.18B – $6.57B · Grade BTODAY
+12 MO
$2.00B
$4.00B
$6.00B
$8.00B
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
2027
Series D $192M
Series F $250M
ValuationBefore first round12-month outlook: where it points, how wide it fansHover the past: the outlook shows what was predicted then
HEADCOUNT · TODAY377 employees
+31%6m growth
+44%1y growth
+151%2y growth
250
500
Data from Jan 2021
Predicted in 1 yr $4.31B +6% vs today
Predicted next raise $475M if a round comes
Winding-down probability 0%
- Last round
- Series F · $250M · Jan 2026
- Valuation at last round
- $3.13B · implied
- Headcount
- 377 · growing
- Grade
- B
- Founded
- 2016
Orca Bio valuation today
VCMC values Orca Bio at $4.1B today, with a range of $2.2B to $6.6B and a grade of B. The valuation starts from its last funding round, a Series F round in Jan 2026.
Valuation by date (133 rows)
Each point is what the model would have shown on that date, using only what was known then; before its first round, a company is valued as a startup because it later raised.
| Date | Valuation | Range | Predicted in 1 yr | Phase | Headcount | Trend | Grade | Winding-down probability |
|---|---|---|---|---|---|---|---|---|
| 1 Jan 2016 | $5.51M | $2.00M – $15.1M | $6.60M (+20%) | before first round | – | unknown | D | 0% |
| 1 Feb 2016 | $5.53M | $2.01M – $15.2M | $6.78M (+23%) | before first round | – | unknown | D | 0% |
| 1 Mar 2016 | $5.55M | $2.02M – $15.2M | $6.95M (+25%) | before first round | – | unknown | D | 0% |
| 1 Apr 2016 | $5.57M | $2.03M – $15.3M | $7.14M (+28%) | before first round | – | unknown | D | 0% |
| 1 May 2016 | $5.59M | $2.04M – $15.4M | $7.33M (+31%) | before first round | – | unknown | D | 0% |
| 1 Jun 2016 | $5.61M | $2.04M – $15.4M | $7.53M (+34%) | before first round | – | unknown | D | 0% |
| 1 Jul 2016 | $5.64M | $2.05M – $15.5M | $7.72M (+37%) | before first round | – | unknown | D | 0% |
| 1 Aug 2016 | $5.79M | $2.11M – $15.9M | $7.93M (+37%) | before first round | – | unknown | D | 0% |
| 1 Sep 2016 | $5.94M | $2.16M – $16.3M | $8.15M (+37%) | before first round | – | unknown | D | 0% |
| 1 Oct 2016 | $6.10M | $2.22M – $16.8M | $8.36M (+37%) | before first round | – | unknown | D | 0% |
| 1 Nov 2016 | $6.26M | $2.28M – $17.2M | $8.59M (+37%) | before first round | – | unknown | D | 0% |
| 1 Dec 2016 | $6.43M | $2.34M – $17.7M | $8.81M (+37%) | before first round | – | unknown | D | 0% |
| 1 Jan 2017 | $6.60M | $2.40M – $18.1M | $9.05M (+37%) | before first round | – | unknown | D | 0% |
| 1 Feb 2017 | $6.78M | $2.47M – $18.6M | $9.29M (+37%) | before first round | – | unknown | D | 0% |
| 1 Mar 2017 | $6.94M | $2.53M – $19.1M | $9.52M (+37%) | before first round | – | unknown | D | 0% |
| 1 Apr 2017 | $7.13M | $2.60M – $19.6M | $9.78M (+37%) | before first round | – | unknown | D | 0% |
| 1 May 2017 | $7.32M | $2.67M – $20.1M | $10.0M (+37%) | before first round | – | unknown | D | 0% |
| 1 Jun 2017 | $7.52M | $2.74M – $20.7M | $10.3M (+37%) | before first round | – | unknown | D | 0% |
| 1 Jul 2017 | $7.72M | $2.81M – $21.2M | $10.6M (+37%) | before first round | – | unknown | D | 0% |
| 1 Aug 2017 | $7.93M | $2.89M – $21.8M | $10.9M (+37%) | before first round | – | unknown | D | 0% |
| 1 Sep 2017 | $8.14M | $2.96M – $22.4M | $11.2M (+37%) | before first round | – | unknown | D | 0% |
| 1 Oct 2017 | $8.36M | $3.04M – $23.0M | $11.5M (+37%) | before first round | – | unknown | D | 0% |
| 1 Nov 2017 | $8.58M | $3.12M – $23.6M | $11.8M (+37%) | before first round | – | unknown | D | 0% |
| 1 Dec 2017 | $8.81M | $3.21M – $24.2M | $12.1M (+37%) | before first round | – | unknown | D | 0% |
| 1 Jan 2018 | $9.05M | $3.29M – $24.9M | $12.4M (+37%) | before first round | – | unknown | D | 0% |
| 1 Feb 2018 | $9.29M | $3.38M – $25.5M | $12.7M (+37%) | before first round | – | unknown | D | 0% |
| 1 Mar 2018 | $9.52M | $3.47M – $26.2M | $13.1M (+37%) | before first round | – | unknown | D | 0% |
| 1 Apr 2018 | $9.78M | $3.56M – $26.9M | $13.4M (+37%) | before first round | – | unknown | D | 0% |
| 1 May 2018 | $10.0M | $3.65M – $27.6M | $13.8M (+37%) | before first round | – | unknown | D | 0% |
| 1 Jun 2018 | $10.3M | $3.75M – $28.3M | $14.1M (+37%) | before first round | – | unknown | D | 0% |
| 1 Jul 2018 | $10.6M | $3.85M – $29.1M | $14.5M (+37%) | before first round | – | unknown | D | 0% |
| 1 Aug 2018 | $10.9M | $3.96M – $29.9M | $14.7M (+35%) | before first round | – | unknown | D | 0% |
| 1 Sep 2018 | $11.2M | $4.06M – $30.7M | $14.8M (+32%) | before first round | – | unknown | D | 0% |
| 1 Oct 2018 | $11.5M | $4.17M – $31.5M | $14.9M (+30%) | before first round | – | unknown | D | 0% |
| 1 Nov 2018 | $11.8M | $4.28M – $32.3M | $15.1M (+28%) | before first round | – | unknown | D | 0% |
| 1 Dec 2018 | $12.1M | $4.40M – $33.2M | $15.2M (+26%) | before first round | – | unknown | D | 0% |
| 1 Jan 2019 | $12.4M | $4.52M – $34.1M | $15.3M (+24%) | before first round | – | unknown | D | 0% |
| 1 Feb 2019 | $12.7M | $4.64M – $35.0M | $15.5M (+21%) | before first round | – | unknown | D | 0% |
| 1 Mar 2019 | $13.1M | $4.75M – $35.9M | $15.6M (+19%) | before first round | – | unknown | D | 0% |
| 1 Apr 2019 | $13.4M | $4.88M – $36.8M | $15.7M (+17%) | before first round | – | unknown | D | 0% |
| 1 May 2019 | $13.8M | $5.01M – $37.8M | $15.9M (+15%) | before first round | – | unknown | D | 0% |
| 1 Jun 2019 | $14.1M | $5.15M – $38.8M | $16.0M (+13%) | before first round | – | unknown | D | 0% |
| 1 Jul 2019 | $14.5M | $5.28M – $39.8M | $16.2M (+11%) | before first round | – | unknown | D | 0% |
| 1 Aug 2019 | $14.7M | $5.33M – $40.2M | $16.3M (+11%) | before first round | – | unknown | D | 0% |
| 1 Sep 2019 | $14.8M | $5.38M – $40.6M | $16.5M (+11%) | before first round | – | unknown | D | 0% |
| 1 Oct 2019 | $14.9M | $5.43M – $41.0M | $16.6M (+11%) | before first round | – | unknown | D | 0% |
| 1 Nov 2019 | $15.1M | $5.48M – $41.4M | $16.8M (+11%) | before first round | – | unknown | D | 0% |
| 1 Dec 2019 | $15.2M | $5.53M – $41.7M | $16.9M (+11%) | before first round | – | unknown | D | 0% |
| 1 Jan 2020 | $15.3M | $5.58M – $42.1M | $17.1M (+11%) | before first round | – | unknown | D | 0% |
| 1 Feb 2020 | $15.5M | $5.63M – $42.5M | $17.2M (+11%) | before first round | – | unknown | D | 0% |
| 1 Mar 2020 | $15.6M | $5.68M – $42.9M | $17.4M (+11%) | before first round | – | unknown | D | 0% |
| 1 Apr 2020 | $15.7M | $5.73M – $43.3M | $17.5M (+11%) | before first round | – | unknown | D | 0% |
| 1 May 2020 | $15.9M | $5.78M – $43.6M | $17.7M (+11%) | before first round | – | unknown | D | 0% |
| 1 Jun 2020 | $16.0M | $5.84M – $44.0M | $17.9M (+11%) | before first round | – | unknown | D | 0% |
| 18 Jun 2020 | $2.4B | $1.6B – $4.7B | $3.1B (+30%) | after a round | – | unknown | B | 0% |
| 1 Jul 2020 | $2.4B | $1.6B – $4.7B | $3.1B (+29%) | after a round | – | unknown | B | 0% |
| 1 Aug 2020 | $2.5B | $1.6B – $4.7B | $3.1B (+26%) | after a round | – | unknown | B | 0% |
| 1 Sep 2020 | $2.5B | $1.6B – $4.7B | $3.1B (+23%) | after a round | – | unknown | B | 0% |
| 1 Oct 2020 | $2.6B | $1.6B – $4.7B | $3.1B (+20%) | after a round | – | unknown | B | 0% |
| 1 Nov 2020 | $2.6B | $1.6B – $4.7B | $3.1B (+18%) | after a round | – | unknown | B | 0% |
| 1 Dec 2020 | $2.7B | $1.6B – $4.7B | $3.1B (+15%) | after a round | – | unknown | B | 0% |
| 1 Jan 2021 | $2.8B | $1.6B – $4.7B | $3.1B (+13%) | after a round | 31 | unknown | B | 0% |
| 1 Feb 2021 | $2.8B | $1.6B – $4.7B | $3.1B (+10%) | after a round | 31 | unknown | B | 0% |
| 1 Mar 2021 | $2.9B | $1.6B – $4.7B | $3.1B (+8%) | after a round | 31 | unknown | B | 0% |
| 1 Apr 2021 | $3.0B | $1.6B – $4.7B | $3.1B (+6%) | after a round | 31 | flat | B | 0% |
| 1 May 2021 | $3.0B | $1.6B – $4.7B | $3.1B (+3%) | after a round | 31 | flat | B | 0% |
| 1 Jun 2021 | $3.1B | $1.6B – $4.7B | $3.1B (+1%) | after a round | 31 | flat | B | 0% |
| 1 Jul 2021 | $3.1B | $1.5B – $4.7B | $3.1B (0%) | after a round | 31 | flat | B | 0% |
| 1 Aug 2021 | $3.1B | $1.5B – $4.7B | $3.1B (0%) | after a round | 31 | flat | B | 0% |
| 1 Sep 2021 | $3.1B | $1.4B – $4.7B | $3.1B (0%) | after a round | 31 | flat | C | 0% |
| 1 Oct 2021 | $3.1B | $1.3B – $4.7B | $3.1B (0%) | after a round | 31 | flat | C | 0% |
| 1 Nov 2021 | $3.1B | $1.3B – $4.7B | $3.1B (0%) | after a round | 31 | flat | C | 0% |
| 1 Dec 2021 | $3.1B | $1.2B – $4.7B | $3.1B (0%) | after a round | 31 | flat | C | 0% |
| 1 Jan 2022 | $3.1B | $1.2B – $4.7B | $3.1B (0%) | after a round | 31 | flat | C | 0% |
| 1 Feb 2022 | $3.1B | $1.6B – $4.7B | $3.1B (0%) | after a round | 89 | growing | B | 0% |
| 1 Mar 2022 | $3.1B | $1.7B – $4.7B | $3.1B (0%) | after a round | 89 | growing | B | 0% |
| 1 Apr 2022 | $3.1B | $1.7B – $4.7B | $3.1B (0%) | after a round | 89 | growing | B | 0% |
| 1 May 2022 | $3.1B | $1.7B – $4.7B | $3.1B (0%) | after a round | 89 | growing | B | 0% |
| 1 Jun 2022 | $3.1B | $1.7B – $4.7B | $3.1B (0%) | after a round | 89 | growing | B | 0% |
| 1 Jul 2022 | $3.1B | $1.6B – $4.7B | $3.1B (0%) | after a round | 89 | growing | B | 0% |
| 1 Aug 2022 | $3.1B | $1.6B – $4.7B | $3.1B (0%) | after a round | 89 | growing | B | 0% |
| 1 Sep 2022 | $3.1B | $1.6B – $4.7B | $3.1B (0%) | after a round | 89 | growing | B | 0% |
| 1 Oct 2022 | $3.1B | $1.6B – $4.7B | $3.1B (0%) | after a round | 89 | growing | B | 0% |
| 1 Nov 2022 | $3.1B | $692M – $4.7B | $3.1B (0%) | after a round | 89 | unknown | C | 0% |
| 1 Dec 2022 | $3.1B | $658M – $4.7B | $3.1B (0%) | after a round | 89 | unknown | C | 0% |
| 1 Jan 2023 | $3.1B | $626M – $4.7B | $3.1B (0%) | after a round | 89 | unknown | D | 0% |
| 1 Feb 2023 | $3.1B | $595M – $4.7B | $3.1B (0%) | after a round | 89 | unknown | D | 0% |
| 1 Mar 2023 | $3.1B | $568M – $4.7B | $3.1B (0%) | after a round | 89 | unknown | D | 0% |
| 1 Apr 2023 | $3.1B | $1.1B – $4.7B | $3.1B (0%) | after a round | 120 | up | C | 0% |
| 1 May 2023 | $3.1B | $1.0B – $4.7B | $3.1B (0%) | after a round | 120 | up | C | 0% |
| 1 Jun 2023 | $3.1B | $1.0B – $4.7B | $3.1B (0%) | after a round | 120 | up | C | 0% |
| 1 Jul 2023 | $3.1B | $789M – $4.7B | $3.1B (0%) | after a round | 120 | up | C | 0% |
| 1 Aug 2023 | $3.1B | $764M – $4.7B | $3.1B (0%) | after a round | 120 | up | C | 0% |
| 1 Sep 2023 | $3.1B | $420M – $4.7B | $3.1B (0%) | after a round | 120 | unknown | D | 0% |
| 1 Oct 2023 | $3.1B | $400M – $4.6B | $2.8B (-7%) | after a round | 130 | flat | D | 0% |
| 1 Nov 2023 | $3.0B | $380M – $4.6B | $2.8B (-7%) | after a round | 130 | flat | D | 0% |
| 1 Dec 2023 | $3.0B | $361M – $4.6B | $2.8B (-7%) | after a round | 130 | flat | D | 0% |
| 1 Jan 2024 | $3.0B | $344M – $4.6B | $2.8B (-7%) | after a round | 130 | flat | D | 0% |
| 1 Feb 2024 | $3.0B | $629M – $4.6B | $2.9B (-5%) | after a round | 140 | up | C | 0% |
| 1 Mar 2024 | $3.0B | $610M – $4.6B | $2.9B (-5%) | after a round | 140 | up | D | 0% |
| 1 Apr 2024 | $3.0B | $590M – $4.6B | $2.9B (-5%) | after a round | 140 | up | D | 0% |
| 1 May 2024 | $3.0B | $572M – $4.6B | $2.9B (-5%) | after a round | 140 | up | D | 0% |
| 1 Jun 2024 | $3.0B | $553M – $4.5B | $2.8B (-5%) | after a round | 140 | up | D | 0% |
| 1 Jul 2024 | $3.0B | $441M – $4.6B | $3.0B (-3%) | after a round | 150 | up | D | 0% |
| 1 Aug 2024 | $3.0B | $425M – $4.6B | $3.0B (-2%) | after a round | 150 | up | D | 0% |
| 1 Sep 2024 | $3.0B | $410M – $4.6B | $3.0B (-2%) | after a round | 150 | up | D | 0% |
| 1 Oct 2024 | $3.0B | $395M – $4.6B | $3.0B (-2%) | after a round | 150 | up | D | 0% |
| 1 Nov 2024 | $3.0B | $380M – $4.5B | $2.9B (-3%) | after a round | 160 | up | D | 0% |
| 1 Dec 2024 | $3.0B | $367M – $4.5B | $2.9B (-3%) | after a round | 160 | up | D | 0% |
| 1 Jan 2025 | $3.0B | $353M – $4.5B | $2.9B (-3%) | after a round | 160 | up | D | 0% |
| 1 Feb 2025 | $3.0B | $340M – $4.5B | $2.9B (-3%) | after a round | 160 | up | D | 0% |
| 1 Mar 2025 | $2.9B | $329M – $4.5B | $2.8B (-3%) | after a round | 160 | up | D | 0% |
| 1 Apr 2025 | $2.9B | $317M – $4.5B | $2.8B (-3%) | after a round | 160 | up | D | 0% |
| 1 May 2025 | $2.8B | $310M – $4.3B | $2.7B (-5%) | after a round | 160 | up | D | 0% |
| 1 Jun 2025 | $2.8B | $310M – $4.3B | $2.7B (-5%) | after a round | 160 | up | D | 0% |
| 1 Jul 2025 | $2.8B | $310M – $4.2B | $2.6B (-5%) | after a round | 160 | up | D | 0% |
| 1 Aug 2025 | $3.1B | $929M – $4.7B | $3.1B (0%) | after a round | 218 | growing | C | 0% |
| 1 Sep 2025 | $3.1B | $929M – $4.7B | $3.1B (0%) | after a round | 218 | growing | C | 0% |
| 1 Oct 2025 | $3.1B | $929M – $4.7B | $3.1B (0%) | after a round | 261 | growing | C | 0% |
| 1 Nov 2025 | $3.1B | $929M – $4.7B | $3.1B (0%) | after a round | 281 | growing | C | 0% |
| 1 Dec 2025 | $3.1B | $929M – $4.7B | $3.1B (0%) | after a round | 281 | growing | C | 0% |
| 1 Jan 2026 | $3.1B | $2.1B – $6.2B | $4.1B (+30%) | after a round | 281 | growing | B | 0% |
| 2 Jan 2026 | $3.1B | $2.1B – $6.2B | $4.1B (+30%) | after a round | 281 | growing | B | 0% |
| 1 Feb 2026 | $3.2B | $2.1B – $6.2B | $4.1B (+27%) | after a round | 287 | growing | B | 0% |
| 1 Mar 2026 | $3.3B | $2.1B – $6.2B | $4.1B (+25%) | after a round | 287 | growing | B | 0% |
| 1 Apr 2026 | $3.3B | $2.1B – $6.2B | $4.1B (+22%) | after a round | 287 | growing | B | 0% |
| 1 May 2026 | $3.4B | $2.1B – $6.3B | $4.2B (+21%) | after a round | 318 | growing | B | 0% |
| 1 Jun 2026 | $3.5B | $2.1B – $6.4B | $4.2B (+19%) | after a round | 336 | growing | B | 0% |
| 1 Jul 2026 | $3.6B | $2.1B – $6.4B | $4.2B (+16%) | after a round | 336 | growing | B | 0% |
| 1 Aug 2026 | $3.7B | $2.1B – $6.4B | $4.2B (+13%) | after a round | 336 | growing | B | 0% |
| 1 Sep 2026 | $3.8B | $2.1B – $6.4B | $4.2B (+10%) | after a round | 336 | growing | B | 0% |
| 1 Oct 2026 | $4.0B | $2.2B – $6.6B | $4.3B (+8%) | after a round | 377 | growing | B | 0% |
| 24 Oct 2026 | $4.1B | $2.2B – $6.6B | $4.3B (+6%) | after a round | 377 | growing | B | 0% |
Key facts about Orca Bio
- Founded
- 2016
- Headquarters
- Menlo Park, United States
- Employees
- about 377 +44% in a year
- Total raised
- $442M
- Funding rounds
- 3
- Last round
- Debt Jan 2026
Orca Bio was founded in 2016 by Ivan Dimov and Nathaniel Fernhoff.
Orca Bio funding history
Orca Bio has 3 funding rounds on record, from Jun 2020 to Jan 2026, $442M in total. None disclosed a valuation.
Amount undisclosed
Series F 1 Jan 2026
Led by Lightspeed Venture Partners.
Sources: orcabio.com, fiercepharma.com, finsmes.com and 1 more
$250M
Series D 17 Jun 2020
Led by Lightspeed Venture Partners, Undisclosed Investor; with 8VC, DCVC, ND Capital, Mubadala, Kaiser Permanente Ventures, Kaiser Permanente Group Trust, IMRF.
Sources: orcabio.com, globalgenes.org, biospace.com and 3 more
$192M
Orca Bio investors
10 investors have backed Orca Bio; Lightspeed Venture Partners and Undisclosed Investor led at least one round.
- Lightspeed Venture Partners lead, 2 rounds
- Undisclosed Investor lead
- 8VC
- DCVC
- IMRF
- Kaiser Permanente Group Trust
- Mubadala
- Silicon Valley Bank
What Orca Bio does
Orca Bio works in pharmaceutical products, with 12 recorded offerings and customers in biotechnology and healthcare.
Orca Biosystems Inc. is an American biotechnology company engaged in the development of cell therapies for cancer and autoimmune diseases. The company specializes in the creation of allogeneic T-cell immunotherapies, including investigational products designed to replace diseased blood and immune systems with healthy ones. Orca Bio operates a centralized manufacturing facility in Sacramento, California, supporting the production of its therapies at scale. The company also conducts clinical research and development for blood cancers and autoimmune disorders.
Description from Veridion's company data.
Products and services
- Cell Therapy Development
- Allogeneic T-Cell Immunotherapy Development
- Blood Cancer Cell Therapy Development
- Autoimmune Disease Cell Therapy Development
- Precision Cell Therapy Manufacturing
- Immune Reconstitution Therapy Development
- Proprietary Cell Therapy Product Manufacturing
- Centralized Cell Therapy Manufacturing
- Patient-Centric Cell Therapy Solutions
- Biotechnology Technology Advancement
- Oncology Cell Therapy Development
- Autoimmune Disease Cell Therapy Development
Markets
- Biotechnology
- Healthcare
Technology
- Precision Cell Therapy Development
- Allogeneic T-Cell Immunotherapy
- Single-Cell Precision Manufacturing
Business model
- Business-to-Business
- Manufacturing
Industry codes (NAICS)
- 325414 Biological Product (except Diagnostic) Manufacturing 100% match
Questions about Orca Bio
What is Orca Bio worth?
Valuation $4.1B (range $2.2B to $6.6B), as of 24 Oct 2026.
Has Orca Bio raised money?
Orca Bio has 3 funding rounds on record, from Jun 2020 to Jan 2026, $442M in total. None disclosed a valuation.
Who has invested in Orca Bio?
Lightspeed Venture Partners, Undisclosed Investor, 8VC, DCVC, IMRF and Kaiser Permanente Group Trust, and 4 more. Lead investors include Lightspeed Venture Partners and Undisclosed Investor.
How many people work at Orca Bio?
About 377, up 44% over the last year. Headcount grew from 31 in Jan 2021 to 377 in Sep 2026.
What does Orca Bio do?
Orca Bio works in pharmaceutical products, with 12 recorded offerings and customers in biotechnology and healthcare. Its main offerings are cell therapy development, allogeneic t-cell immunotherapy development and blood cancer cell therapy development.
When was Orca Bio founded, and where is it based?
Orca Bio was founded in 2016 and is based in Menlo Park, United States. It has about 377 employees, up 44% over the last year.